Episode Details

Back to Episodes
Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo

Pharmaceutical Executive Daily: CVS Health to Offer Zepbound and Foundayo

Published 1 month, 2 weeks ago
Description
In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s Zepbound while adding the company’s newly approved obesity pill Foundayo, and experts discuss how treatment expectations are evolving in lupus care.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us